PET and PET/CT in radiation treatment planning for prostate cancer

References

• Emonds KM, Swinnen JV, Mortelmans L, Mottaghy FM. Molecular imaging of prostate cancer. Methods48, 193–199 (2009).
   PubMedGoogle Scholar
• Effert PJ, Bares R, Handt S et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J. Urol.155, 994–998 (1996).
   PubMed Web of Science ®Google Scholar
• Picchio M, Briganti A, Fanti S et al. The Role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur. Urol.59, 51–60 (2011).
   PubMed Web of Science ®Google Scholar
• Seppälä J, Seppänen M, Arponen E, Lindholm P, Minn H. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer. Radiother. Oncol.93, 234–240 (2009).
   PubMed Web of Science ®Google Scholar
• Kotzerke J, Volkmer BG, Glatting G et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmed.42, 25–30 (2003).
   PubMedGoogle Scholar
• Mazaheri Y, Shukla-Dave A, Hricak H et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging – correlation with pathologic findings. Radiology246, 480–488 (2008).
   PubMed Web of Science ®Google Scholar
• Farsad M, Schiavina R, Castellucci P et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J. Nucl. Med.46, 1642–1649 (2005).
   PubMed Web of Science ®Google Scholar
• Kwee SA, Wei H, Sesterhenn I et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J. Nucl. Med.47, 262–269 (2006).
   PubMed Web of Science ®Google Scholar
• Kwee SA, Thibault GP, Stack RS et al. Use of step-section histopathology to evaluate 18F-fluorocholine PET sextant localization of prostate cancer. Mol. Imaging7, 12–20 (2008).
   PubMedGoogle Scholar
• Reske SN, Blumstein NM, Neumaier B et al. Imaging prostate cancer with 11C-choline PET/CT. J. Nucl. Med.47, 1249–1254 (2006).
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Lee J, Uemura H et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur. J. Nucl. Med. Mol. Imaging32, 742–748 (2005).
   PubMed Web of Science ®Google Scholar
• Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J. Nucl. Med.44, 1804–1805 (2003).
   PubMedGoogle Scholar
• Villeirs GM, Verstraete KL, De Neve WJ, De Meerleer GO. Magnetic resonance imaging anatomy of the prostate and periprostatic area: a guide for radiotherapists. Radiother. Oncol.76, 99–106 (2005).
   PubMed Web of Science ®Google Scholar
• Viani GA, Stefano EJ, Alfonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int. J. Radiat. Oncol. Biol. Phys.74, 1405–1418 (2009).
   PubMed Web of Science ®Google Scholar
• Brenner DJ. Fractionation and late rectal toxicity. Int. J. Radiat. Oncol. Biol. Phys.60, 1013–1015 (2004).
   PubMed Web of Science ®Google Scholar
• Pinkawa M, Attieh C, Piroth MD et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer –evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiother. Oncol.93, 213–219 (2009).
   PubMedGoogle Scholar
• Cellini N, Morganti AG, Mattiucci GC et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int. J. Radiat. Oncol. Biol. Phys.53, 595–599 (2002).
   PubMed Web of Science ®Google Scholar
• Chen ME, Johnston DA, Tang K et al. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer89, 1800–1809 (2000).
   PubMed Web of Science ®Google Scholar
• Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int. J. Radiat. Oncol. Biol. Phys.48, 7–16 (2000).
   PubMed Web of Science ®Google Scholar
• Jones HA, Antonini N, Hart AA et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J. Clin. Oncol.27, 4939–4947 (2009).
   PubMed Web of Science ®Google Scholar
• Pinkawa M, Pursch-Lee M, Asadpour B et al. Image-guided radiotherapy for prostate cancer. Implementation of ultrasound-based prostate localization for the analysis of inter- and intrafraction motion. Strahlenther. Onkol.184, 679–685 (2008).
   PubMed Web of Science ®Google Scholar
• de Crevoisier R, Tucker SL, Dong L et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.62, 965–973 (2005).
   PubMed Web of Science ®Google Scholar
• Nederveen AJ, Dehnad H, van der Heide UA et al. Comparison of megavoltage position verification for prostate irradiation based on bony anatomy and implanted fiducials. Radiother. Oncol.68, 81–88 (2003).
   PubMedGoogle Scholar
• Paskalev K, Ma CM, Jacob R et al. Daily target localization for prostate patients based on 3D image correlation. Phys. Med. Biology49, 931–939 (2004).
   PubMedGoogle Scholar
• Pinkawa M, Holy R, Piroth MD et al. Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost. Strahlenther. Onkol.186, 600–606 (2010).
   PubMedGoogle Scholar
• Zhang P, Happersett L, Hunt M et al. Volumetric modulated arc therapy: planning and evaluation for prostate cancer cases. Int. J. Radiat. Oncol. Biol. Phys.76, 1456–1462 (2010).
   PubMed Web of Science ®Google Scholar
• Fonteyne V, Villeirs G, Speleers B et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int. J. Radiat. Oncol. Biol. Phys.72, 799–807 (2008).
   PubMed Web of Science ®Google Scholar
• Susil RC, McNutt TR, DeWeese TL, Song D. Effects of prostate-rectum separation on rectal dose from external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.76, 1251–1258 (2010).
   PubMed Web of Science ®Google Scholar
• Picchio M, Crivellaro C, Giovacchini G, Gianolli L, Messa C. PET-CT for treatment planning in prostate cancer. QJ. Nucl. Med. Mol. Imaging53, 245–268 (2009).
   PubMedGoogle Scholar
• Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J. Nucl. Med.45, 1431–1434 (2004).
   PubMed Web of Science ®Google Scholar
• Sutinen E, Nurmi M, Roivainen A et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur. J. Nucl. Med. Mol. Imaging31, 317–324 (2004).
   PubMed Web of Science ®Google Scholar
• Giovacchini G, Picchio M, Coradeschi E et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur. J. Nucl. Med. Mol. Imaging35, 1065–1073 (2008).
   PubMedGoogle Scholar
• Piert M, Park H, Khan A et al. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J. Nucl. Med.50, 1585–1593 (2009).
   PubMed Web of Science ®Google Scholar
• Pinkawa M. External beam radiotherapy for prostate cancer. Panminerva Med.52, 195–207 (2010).
   PubMedGoogle Scholar
• King CR, Kapp DS, King CR, Kapp DS. Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int. J. Radiat. Oncol. Biol. Phys.71, 346–350 (2008).
   PubMed Web of Science ®Google Scholar
• Rinnab L, Mottaghy FM, Blumstein NM et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int.100, 786–793 (2007).
   PubMedGoogle Scholar
• Rinnab L, Simon J, Hautmann RE et al. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J. Urol.27, 619–625 (2009).
   PubMed Web of Science ®Google Scholar
• Giovacchini G, Picchio M, Coradeschi E et al. Predictive factors of Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging37, 301–309 (2010).
   PubMed Web of Science ®Google Scholar
• de Jong IJ, Pruim J, Elsinga PH et al.11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur. Urol.44, 32–38 (2003).
   PubMedGoogle Scholar
• Giovacchini G, Picchio M, Scattoni V et al. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging37, 1106–1116 (2010).
   PubMedGoogle Scholar
• Stephenson AJ, Scardino PT, Kattan MW et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J. Clin. Oncol.25, 2035–2041 (2007).
   PubMed Web of Science ®Google Scholar